newest glp 1 drug Eli Lilly to seek approval of new GLP-1 weight-loss this year End of GLP-1 Shortages Puts
Description
Enhanced Cardiometabolic Benefits: Studies suggest that multi-receptor agonists lower cardiovascular risk factors, including lipid profiles, blood pressure, and inflammation markers
Nonetheless, given the heterogeneity of available data and the presence of residual uncertainty, a cautious and individualized clinical approach remains warranted
Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index
Novel angiogenesis role of GLP-1(3236) to rescue diabetic ischemic lower limbs via GLP-1R-dependent glycolysis in mice
When it comes to clinical manufacturing, research-grade standards that are good for early finding are no longer enough
